Twist Bioscience Net Income 2017-2021 | TWST

Twist Bioscience net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Twist Bioscience Annual Net Income
(Millions of US $)
2021 $-152
2020 $-140
2019 $-108
2018 $-71
2017 $-59
2016 $-44
Twist Bioscience Quarterly Net Income
(Millions of US $)
2021-09-30 $-41
2021-06-30 $-40
2021-03-31 $-38
2020-12-31 $-33
2020-09-30 $-24
2020-06-30 $-28
2020-03-31 $-32
2019-12-31 $-56
2019-09-30 $-31
2019-06-30 $-28
2019-03-31 $-26
2018-12-31 $-23
2018-09-30 $-20
2018-06-30 $-18
2018-03-31 $-17
2017-12-31 $-17
2017-09-30
2016-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.683B $0.132B
Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81